Affiliations 

  • 1 School of Health Sciences, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia
  • 2 School of Medicine, University of Western Australia, Perth, WA, Australia
  • 3 Department of Genomic Health, Geisinger, Danville, PA, USA
  • 4 Lipid Clinic, Heart Institute (InCor), University of São Paulo, São Paulo, Brazil
  • 5 Department of Medicine and Robarts Research Institute, Schulich School of Medicine, Western University, London, ON, Canada
  • 6 Department of Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
  • 7 23andMe, Sunnyvale, CA, USA
  • 8 Medical Research Centre, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Oman
  • 9 Division of Lipidology and Cape Heart Institute, Department of Medicine, University of Cape Town, Cape Town, South Africa
  • 10 FH Europe Foundation, Amsterdam, The Netherlands
  • 11 Department of Paediatrics, Harvard Medical School, Boston, MA, USA
  • 12 International Atherosclerosis Society, Milan, Italy
  • 13 Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
  • 14 Fundación Hipercolesterolemia Familiar, Madrid, Spain
  • 15 Institute of Pathology, Laboratory and Forensic Medicine (I-PPerForM) and Faculty of Medicine, Universiti Teknologi MARA, Sungai Buloh, Selangor, Malaysia
  • 16 Royal Free London NHS Foundation Trust, University College London, London, UK
  • 17 Imperial Centre for Cardiovascular Disease Prevention, Imperial College London, London, UK
  • 18 Department of Cardiology, Rinku General Medical Center, Osaka, Japan
  • 19 Hammersmith Hospital, Imperial College London, London, UK
Am J Prev Cardiol, 2025 Jun;22:100993.
PMID: 40297674 DOI: 10.1016/j.ajpc.2025.100993

Abstract

Familial hypercholesterolaemia (FH) is the most common monogenic condition associated with premature atherosclerotic cardiovascular disease. Early detection and initiation of cholesterol lowering therapy combined with lifestyle changes improves the prognosis of patients with FH significantly. The International Atherosclerosis Society (IAS) published a new guidance for implementing best practice in the care of FH. Previous guidelines and position statements seldom provided implementation recommendations. To address this, an implementation science approach was used to generate implementation strategies for the clinical recommendations made. This process entailed the generation by consensus of strong implementation recommendations according to the Expert Recommendations for Implementing Change (ERIC) taxonomy. A total of 80 general and specific implementation recommendations were generated, addressing detection (screening, diagnosis, genetic testing and counselling) and management (risk stratification, treatment of adults or children with heterozygous or homozygous FH, therapy during pregnancy and use of apheresis) of patients with FH. We describe here the IAS guidance core implementation strategies to assist with the adoption of clinical recommendations into routine practice for at-risk patients and families worldwide. We summarise the IAS guidance core implementation strategies as operative statements.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Similar publications